ICCM Revenue and Competitors

Kettering, UK

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • ICCM's estimated annual revenue is currently $22.9M per year.(i)
  • ICCM's estimated revenue per employee is $270,000

Employee Data

  • ICCM has 85 Employees.(i)
  • ICCM grew their employee count by 5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.6M520%N/AN/A
#2
$37M1375%N/AN/A
#3
$16.5M68-16%N/AN/A
#4
$42.5M1434%N/AN/A
#5
$48.4M1636%N/AN/A
#6
$25.1M930%N/AN/A
#7
$8.6M4011%N/AN/A
#8
$234.2M6945%N/AN/A
#9
$85.5M28810%N/AN/A
#10
$24.8M927%N/AN/A
Add Company

ICCM Ltd is a national specialist provider of complex care for adults and children with profound disabilities who choose to live in their own homes. We specialise in the fields of spinal cord injury, domiciliary ventilation, acquired brain injury and other neurological disorders.

keywords:N/A

N/A

Total Funding

85

Number of Employees

$22.9M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ICCM's People

NameTitleEmail/Phone
1
Clinical Nurse SpecialistReveal Email/Phone
2
Senior Recruitment CoordinatorReveal Email/Phone
3
Head NursingReveal Email/Phone
4
Clinical NurseReveal Email/Phone

ICCM News

2022-04-19 - Ra Medical Systems (NYSE:RMED) and IceCure Medical ...

Ra Medical Systems (NYSE:RMED) and IceCure Medical (NASDAQ:ICCM) Head to Head Analysis. Posted by admin on Apr 25th, 2022.

2022-04-17 - IceCure Medical (TLV:ICCM) shareholder returns have been solid, earning 241% in 5 years

IceCure Medical (TLV:ICCM) shareholder returns have been solid, earning 241% in 5 years. By: Simply Wall St. Published: April 21, 2022. TASE:ICCM...

2022-04-17 - Financial Survey: IceCure Medical (NASDAQ:ICCM) vs ...

Financial Survey: IceCure Medical (NASDAQ:ICCM) vs. Westaim (OTCMKTS:WEDXF). Posted by admin on Apr 23rd, 2022. Share on Twitter Share on Facebook Share on...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21.5M86-10%N/A
#2
$15.1M879%N/A
#3
$15M105-2%N/A
#4
$15M1203%N/A
#5
$15M1212%N/A